We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RAFA market cap is 9.65M. The company's latest EPS is USD 0.0565 and P/E is 1.95.
| Year End December 30 2022 | 2019 | 2020 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 11.44M | 11.44M | 74.73M | 77.41M | 64.31M |
| Operating Income | 3.09M | 3.09M | 19.08M | 14.73M | 7.15M |
| Net Income | 3.05M | 3.06M | 14.85M | 11.57M | 4.96M |
| Year End December 30 2022 | 2019 | 2020 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 20.53M | 20.53M | 70.63M | 89.34M | 98.32M |
| Total Liabilities | 11.4M | 11.4M | 18.54M | 19.84M | 20.43M |
| Total Equity | 9.13M | 9.13M | 52.1M | 69.51M | 77.89M |
| Year End December 30 2022 | 2019 | 2020 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | N/A | 10.03M | -9.14M | 4.9M | 17.52M |
| Investing | N/A | -9.34M | 7.96M | 6.86M | -11.73M |
| Financing | N/A | 145k | 3.31M | -3.6M | -1.34M |
| Market Cap | 9.65M |
| Price to Earnings Ratio | 1.95 |
| Price to Sales Ratio | 0.15 |
| Price to Cash Ratio | 0.54 |
| Price to Book Ratio | 0.12 |
| Dividend Yield | - |
| Shares Outstanding | 87.77M |
| Average Volume (1 week) | 51.83k |
| Average Volume (1 Month) | 33.76k |
| 52 Week Change | -56.00% |
| 52 Week High | 0.427 |
| 52 Week Low | 0.084 |
| Spread (Intraday) | 0.04 (25.68%) |
| Company Name | Rafarma Pharmaceuticals Inc (PK) |
| Address |
203 s. main sheridan, wyoming 82801 |
| Website | https://rafarma.si |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
